CN104902958A - 用于治疗神经退行性疾病的拉喹莫德和普利多匹定 - Google Patents

用于治疗神经退行性疾病的拉喹莫德和普利多匹定 Download PDF

Info

Publication number
CN104902958A
CN104902958A CN201380050913.8A CN201380050913A CN104902958A CN 104902958 A CN104902958 A CN 104902958A CN 201380050913 A CN201380050913 A CN 201380050913A CN 104902958 A CN104902958 A CN 104902958A
Authority
CN
China
Prior art keywords
laquinimod
amount
puli
many
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380050913.8A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·海登
丹·巴尔-佐哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN104902958A publication Critical patent/CN104902958A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380050913.8A 2012-09-27 2013-09-27 用于治疗神经退行性疾病的拉喹莫德和普利多匹定 Pending CN104902958A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US61/706,695 2012-09-27
US201361879004P 2013-09-17 2013-09-17
US61/879,004 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
CN104902958A true CN104902958A (zh) 2015-09-09

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380050913.8A Pending CN104902958A (zh) 2012-09-27 2013-09-27 用于治疗神经退行性疾病的拉喹莫德和普利多匹定

Country Status (13)

Country Link
US (7) US20140088140A1 (https=)
EP (1) EP2900330A4 (https=)
CN (1) CN104902958A (https=)
AU (1) AU2013323131A1 (https=)
BR (1) BR112015006623A2 (https=)
CA (1) CA2884781A1 (https=)
EA (1) EA201590655A8 (https=)
HK (2) HK1211525A1 (https=)
IL (1) IL237742A0 (https=)
IN (1) IN2015DN03219A (https=)
MX (1) MX2015003608A (https=)
WO (1) WO2014052933A1 (https=)
ZA (1) ZA201502600B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278440A (zh) * 2017-08-14 2020-06-12 普里莱尼亚神经治疗有限公司 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
CN113597310A (zh) * 2019-03-15 2021-11-02 普瑞尼亚神经治疗有限公司 使用普利多匹定治疗线粒体相关疾病和病症，包含其症状

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) * 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
CN121243170A (zh) * 2019-06-12 2026-01-02 普瑞尼亚神经治疗有限公司 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008155357A2 (en) * 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278440A (zh) * 2017-08-14 2020-06-12 普里莱尼亚神经治疗有限公司 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
CN111278440B (zh) * 2017-08-14 2023-04-25 普瑞尼亚神经治疗有限公司 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
CN113597310A (zh) * 2019-03-15 2021-11-02 普瑞尼亚神经治疗有限公司 使用普利多匹定治疗线粒体相关疾病和病症，包含其症状

Also Published As

Publication number Publication date
IL237742A0 (en) 2015-05-31
US20180133209A1 (en) 2018-05-17
WO2014052933A1 (en) 2014-04-03
AU2013323131A1 (en) 2015-05-07
HK1211525A1 (en) 2016-05-27
BR112015006623A2 (pt) 2017-07-04
IN2015DN03219A (https=) 2015-10-02
US20180250285A1 (en) 2018-09-06
US20180369228A1 (en) 2018-12-27
US20140088140A1 (en) 2014-03-27
HK1214553A1 (zh) 2016-07-29
EP2900330A1 (en) 2015-08-05
EA201590655A8 (ru) 2016-07-29
US20150209346A1 (en) 2015-07-30
US20190117639A1 (en) 2019-04-25
US20170319569A1 (en) 2017-11-09
ZA201502600B (en) 2016-06-29
EP2900330A4 (en) 2016-05-25
EA201590655A1 (ru) 2015-12-30
CA2884781A1 (en) 2014-04-03
MX2015003608A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
CN104902958A (zh) 用于治疗神经退行性疾病的拉喹莫德和普利多匹定
JP7069253B2 (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP7066679B2 (ja) 認知症の処置
US20140088145A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
KR20110033852A (ko) 도파민 수용체 리간드를 함유하는 약학적 제형
TW201408299A (zh) 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物
TW201041609A (en) Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido) acetamide compound
KR20150080016A (ko) (티오)-카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
TR201807978T4 (tr) Levosetirizin veya bunun farmasötik olarak kabul edilebilen bir tuzunu ve montelukast veya bunun farmasötik olarak kabul edilebilen bir tuzunu içeren oral uygulama için stabil farmasötik formülasyon.
US6297262B1 (en) Treatment of schizophrenia and psychosis
JPWO2004066998A1 (ja) 安定な経口用固形医薬組成物
US7989479B2 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
JPWO2006107019A1 (ja) うつ病または不安神経症の予防または治療剤
RU2799049C2 (ru) Способы лечения изменений поведения
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Michael's tiopropamine

Inventor before: Michael's tiopropamine

Inventor before: Dan Barr Zohar

COR Change of bibliographic data
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214553

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150909

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214553

Country of ref document: HK